argenx SE (ARGX)
After hours:
| Previous close | 364.35 |
| Open | 365.92 |
| Bid | 373.81 x 1200 |
| Ask | 550.06 x 800 |
| Day's range | 364.43 - 376.55 |
| 52-week range | 249.50 - 376.55 |
| Volume | |
| Avg. volume | 304,883 |
| Market cap | 20.256B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.53 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 390.74 |
- GlobeNewswire
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing authorization application (MAA) expected in approximately 60 days If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG) Breda, the Netherlands—June 24, 2022—argenx (Eur
- GlobeNewswire
argenx to Present at Upcoming Investor Conferences
June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in June: Jefferies 2022 Global Healthcare Conference. Fireside chat on Wednesday, June 8, 2022 at 1:00 p.m. ET in New York, NY.Goldman Sachs 43rd Annual Global Healthcare Conference. Fireside chat on Wednesday, Jun
- GlobeNewswire
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing authorization Efgartigimod was granted a Promising Innovative Medicine (PIM) designation by UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2021 Breda, the Netherlands—May 31, 2022—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives
